HP
AUPH icon

HealthInvest Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

HealthInvest Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$994K Hold
230,000
– – 1.92% 10
2022
Q3 		$1.73M Hold
230,000
– – 3.65% 10
2022
Q2 		$2.31M Buy
+230,000
New +$2.57M 5.33% 12

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HealthInvest Partners's AUPH Position: Q4 2022 in Review

HealthInvest Partners held its Aurinia Pharmaceuticals (AUPH) position steady in Q4 2022 at 230,000 shares worth $994K. The position accounts for 1.92% of the portfolio, ranked #10.

HealthInvest Partners first reported a position in AUPH in Q2 2022 and has held it in 3 quarters since. The position peaked at $2.31M in Q2 2022. 192 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

  • HealthInvest Partners held 230,000 shares of Aurinia Pharmaceuticals worth $994K as of Q4 2022.
  • HealthInvest Partners left its Aurinia Pharmaceuticals share count unchanged in Q4 2022.
  • Aurinia Pharmaceuticals made up 1.92% of HealthInvest Partners's portfolio in Q4 2022, its #10 holding.
  • HealthInvest Partners first reported a position in Aurinia Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
  • HealthInvest Partners's Aurinia Pharmaceuticals position peaked at $2.31M in Q2 2022.
  • 192 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.